• Mashup Score: 0

    NATIONAL HARBOR, Md. — Oral sodium chloride supplementation during IV diuresis resulted in similar changes in serum creatinine and body weight at 96 hours vs. placebo in patients hospitalized for acute HF, a speaker reported.The results of the Oral Sodium to Preserve Renal Efficiency in Acute HF (OSPREY-AHF) trial were presented at the Heart Failure Society of America Annual Scientific

    Tweet Tweets with this article
    • Oral sodium chloride supplementation during IV diuresis resulted in similar changes in serum creatinine and body weight at 96 hours vs. placebo in patients hospitalized for acute HF @ramontgo @CWRUdeptMED @HFSA #HFSA2022 #CardioTwitter https://t.co/0JtQOHJZVO

  • Mashup Score: 2

    NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with HF with improved ejection fraction prior to trial enrollment compared with those with consistently high EF.“Heart failure with improved ejection fraction … has been recently defined as heart failure with previously reduced left ventricular ejection fraction of 40% or less,

    Tweet Tweets with this article
    • In a #DELIVER subgroup analysis, #dapagliflozin conferred similar benefit in patients with HF with improved EF prior to trial enrollment compared with those with consistently high EF @orlyvardeny @UMNews @HFSA #HFSA2022 #Cardiotwitter https://t.co/KMOirNP85U

  • Mashup Score: 0

    NATIONAL HARBOR, Md. — A novel speech analysis system was able to detect impending heart failure events in ambulatory patients with congestive HF more than 3 weeks ahead of time, a speaker reported.The system (HearO, Cordio Medical) was not only able to predict HF events with greater sensitivity compared with daily weight and oxygen saturation monitoring, but also demonstrated fewer average

    Tweet Tweets with this article
    • ICYMI: "This approach has the potential to reduce [acute decompensated] HF hospitalizations and improve patient quality of life and economic outcomes." @TheHeartBeat3 @HFSA #HFSA2022 #CardioTwitter https://t.co/EFCxHArJez

  • Mashup Score: 0

    NATIONAL HARBOR, Md. — A novel speech analysis system was able to detect impending heart failure events in ambulatory patients with congestive HF more than 3 weeks ahead of time, a speaker reported.The system (HearO, Cordio Medical) was not only able to predict HF events with greater sensitivity compared with daily weight and oxygen saturation monitoring, but also demonstrated fewer average

    Tweet Tweets with this article
    • ICYMI: "This approach has the potential to reduce [acute decompensated] HF hospitalizations and improve patient quality of life and economic outcomes." @TheHeartBeat3 @HFSA #HFSA2022 #CardioTwitter https://t.co/EFCxHArJez

  • Mashup Score: 3

    NATIONAL HARBOR, Md. — A novel speech analysis system was able to detect impending heart failure events in ambulatory patients with congestive HF more than 3 weeks ahead of time, a speaker reported.The system (HearO, Cordio Medical) was not only able to predict HF events with greater sensitivity compared with daily weight and oxygen saturation monitoring, but also demonstrated fewer average

    Tweet Tweets with this article
    • A novel #SpeechAnalysis system was able to detect impending #HeartFailure events in ambulatory patients with congestive heart failure more than 3 weeks ahead of time @TheHeartBeat3 @HFSA #HFSA2022 #CardioTwitter https://t.co/EFCxHArJez

  • Mashup Score: 0

    NATIONAL HARBOR, Md. — Among PROVE-HF trial participants with HF with reduced ejection fraction and moderate to severe mitral regurgitation at baseline, sacubitril/valsartan improved mitral regurgitation severity in about half, a speaker reported.However, those who improved in mitral regurgitation severity had similar baseline characteristics as those who did not, according to the

    Tweet Tweets with this article
    • ICYMI: "This has important implications for how long we want to look at and how aggressively we want to try with optimizing [guideline-directed medical therapy] prior to considering mitral intervention.” @DukeHFDoc @DCRINews @HFSA #HFSA2022 #CardioTwitter https://t.co/SiUqqIIWnC

  • Mashup Score: 1

    NATIONAL HARBOR, Md. — Aficamten was associated with sustained improvement in patient-reported symptom burden and quality of life at 6 months when used to treat obstructive hypertrophic cardiomyopathy, a speaker reported.Treatment of obstructive hypertrophic cardiomyopathy (HCM) with aficamten (Cytokinetics), a novel selective cardiac myosin inhibitor, was associated with improvements

    Tweet Tweets with this article
    • ICYMI: “The fact that this drug is capable of making such a significant impact in the day-to-day experience of somebody living with this disease is really profound and impressive.” @S2beri @umichCVC @HFSA #HFSA2022 #CardioTwitter https://t.co/wow5sgY9pn